Biological axis of CXC chemokine ligand and expression of stem cell markers in human colorectal cancer tissues as well as their relationship with clinical and pathological characteristics

doi:10.3969/j.issn.2095-4344.2014.19.025

Abstract

Abstract:

BACKGROUND: The biological axis of CXC chemokine ligand 12 (CXCL12)/CXC chemokine receptor 4 (CXCR4) plays an important role in the specific metastasis of tumors, whereas the mRNA expression of glycoprotein hormone receptor 5, a stem cell marker, exerts an important effects on tumor proliferation, invasion and metastasis.
OBJECTIVE: To investigate the expressions of CXCL12/CXCR4 and glycoprotein hormone receptor 5 in human colorectal cancer tissues as well as their relationship with clinical and pathological characteristics.
METHODS: Totally 100 colorectal cancer patients admitted at Liaoning Cancer Hospital & Institute from January to June 2013 were enrolled as experimental group, and another 100 healthy volunteers served as control group. Immunohistochemical SP method was used to detect the expression of CXCL12, CXCR4 and glycoprotein hormone receptor 5 mRNA in human colorectal cancer tissues. We analyzed the correlation of CXCL12, CXCR4 and glycoprotein hormone receptor 5 mRNA expression with colorectal cancer patients’ age, sex, tumor size and site, lymphatic metastasis and prognosis.
RESULTS AND CONCLUSION: There was a higher expression of CXCR4 and glycoprotein hormone receptor 5 mRNA, but lower expression of CXCL12 mRNA in the human colorectal cancer tissues. The mRNA expression of CXCR4, CXCL12 and glycoprotein hormone receptor 5 showed no correlation with age, gender, tumor size and site of colorectal cancer patients, but was related to lymphatic metastasis. For colorectal cancer patients with lymphatic metastasis, the expression of CXCR4 and glycoprotein hormone receptor 5 mRNA was higher, but no change was found in the expression of CXCL12 mRNA. The expression of CXCR4 was increased with the degree of tumor malignancy as well as glycoprotein hormone receptor 5 expressed on the surface of gastrointestinal cancer and brain tumor stem cells. These findings indicate that the growth and metastasis of human colorectal cancer tissues are promoted by increasing the expression of CXCR4 and glycoprotein hormone receptor 5 in human colorectal cancer tissues; the CXCL12/CXCR4 biological axis and glycoprotein hormone receptor 5 are expected to become a new target therapy for tumor diagnosis and treatment.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: colorectal neoplasms, chemotactic factors, receptors, chemokine, chemokine CXCL12

CLC Number:

R394.2

Huang Zhe. Biological axis of CXC chemokine ligand and expression of stem cell markers in human colorectal cancer tissues as well as their relationship with clinical and pathological characteristics[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(19): 3105-3110.

Figures/Tables 2

References

[1] Ellidag HY, Bulbuller N, Eren E, et al. Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma? Gut Liver. 2013;7(6):675-680.
[2] Hatakeyama T, Nakanishi M, Murayama Y, et al. Laparoscopic resection for colorectal cancer improves short-term outcomes in very elderly colorectal cancer patients. Surg Laparosc Endosc Percutan Tech. 2013; 23(6):532-535.
[3] 卫生部医政司.结直肠癌诊疗规范(2010年版)[J].中国医学前沿杂志(电子版),2011,3(6):130-146.
[4] Tanksley JP, Chen X, Coffey RJ. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. PLoS One. 2013;8(11):e81514.
[5] Dennis DL, Waring JL, Payeur N, et al. Making lifestyle changes after colorectal cancer: insights for program development. Curr Oncol. 2013;20(6):e493-511.
[6] Folse HJ, Green LE, Kress A, et al. Cost-effectiveness of a genetic test for breast cancer risk. Cancer Prev Res (Phila). 2013;6(12):1328-1336.
[7] Arteaga González I, Martín Malagón A, Garcia SG, et al. Single-incision laparoscopic surgery for colon and rectal cancer: an initial experience with the technique. Surg Laparosc Endosc Percutan Tech. 2013;23(6):494-497.
[8] Glenister R, McDaniel K, Francis H, et al. Therapeutic actions of melatonin on gastrointestinal cancer development and progression. Transl Gastrointest Cancer. 2013;2(1).
[9] Park JJ, Lee M. Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver. 2013; 7(6):629-641.
[10] Endo S, Takehara Y, Tanaka J, et al. Complete laparoscopic surgery for early colorectal cancer after endoscopic resection. Asian J Endosc Surg. 2013;6(4):338-341.
[11] Lee H, Flaherty P, Ji HP. Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Med Genomics. 2013;6: 54.
[12] Samardzi? S, Mihaljevi? S, Dmitrovi? B, et al. First six years of implementing colorectal cancer screening in the Osijek-Baranja County, Croatia--can we do better? Coll Antropol. 2013;37(3):913-918.
[13] 崔同建,陈义乾,戴永美等.大肠癌中医证型与ERCC1基因多态性的相关研究[J].中国中西医结合杂志,2012,32(5):628-632.
[14] Fu JF, Huang YQ, Yang J, et al. Clinical characteristics and prognosis of young patients with colorectal cancer in Eastern China. World J Gastroenterol. 2013;19(44):8078-8084.
[15] Marques I, Araújo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol. 2013;19(44):7955-7971.
[16] 谷学军,秦望森,许金玲.血清CA125联合CA19-9及CEA检测应用于大肠癌诊断的临床价值[J].中国实验诊断学,2012,16(6): 1047-1049.
[17] He Z, Subramaniam D, Zhang Z, et al. Honokiol as a Radiosensitizing Agent for Colorectal cancers. Curr Colorectal Cancer Rep. 2013;9(4).
[18] Andrews L. Dietary flavonoids for the prevention of colorectal cancer. Clin J Oncol Nurs. 2013;17(6):671-672.
[19] Osumi H, Matsusaka S, Shinozaki E, et al. Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC Res Notes. 2013;6:508.
[20] Luckmann R, Costanza ME, Rosal M, et al. Referring patients for telephone counseling to promote colorectal cancer screening. Am J Manag Care. 2013;19(9):702-708.
[21] Madhavan S, Gauba R, Song L, et al. Platform for Personalized Oncology: Integrative analyses reveal novel molecular signatures associated with colorectal cancer relapse. AMIA Summits Transl Sci Proc. 2013;2013:118.
[22] Wagholikar K, Sohn S, Wu S, et al. Workflow-based data reconciliation for clinical decision support: case of colorectal cancer screening and surveillance. AMIA Summits Transl Sci Proc. 2013;2013:269-273.
[23] Arteaga González I, Martín Malagón A, Garcia SG, et al. Single-incision laparoscopic surgery for colon and rectal cancer: an initial experience with the technique. Surg Laparosc Endosc Percutan Tech. 2013;23(6):494-497.
[24] Transanal endoscopic operations in the complex treatment of the complicated colorectal cancer. Khirurgiia (Mosk). 2013; (11):67-68.
[25] Kakugawa Y, Saito Y, Matsuda T, et al. Colorectal laterally spreading tumors by computed tomographic colonography. Int J Mol Sci. 2013;14(12):23629-23638.
[26] Fournier A, Hill C. Drugs and cancer risk: the example of THM. Rev Prat. 2013;63(8):1117-1121.
[27] 王晓戎,袁孝兵,储慧琴,等.因子分析和聚类分析联合应用在大肠癌证候分布中的研究[J].时珍国医国药,2012,23(5): 1194-1195.
[28] Gill P, Rafferty H, Munday D, et al. Proximal colon cancer and serrated adenomas - hunting the missing 10%. Clin Med. 2013; 13(6):557-561.
[29] Min MR, Chowdhury S, Qi Y, et al. An integrated approach to blood-based cancer diagnosis and biomarker discovery. Pac Symp Biocomput. 2014:87-98.
[30] McLaughlan J, Ingram N, Smith PR, et al. Increasing the sonoporation efficiency of targeted polydisperse microbubble populations using chirp excitation. IEEE Trans Ultrason Ferroelectr Freq Control. 2013;60(12):2511-2520.
[31] Halabi WJ, Jafari MD, Nguyen VQ, et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg. 2013;206(6):1024-1033.
[32] Shukla RK. Recent advances in oral anticancer agents for colon cancer. Future Oncol. 2013;9(12):1893-1908.
[33] Hudson AG, Mertz KJ, Jubelirer SJ, et al. Cancer incidence in elderly West Virginians. W V Med J. 2013;109(5):8-12.
[34] Pericleous M, Mandair D, Caplin ME. Diet and supplements and their impact on colorectal cancer. J Gastrointest Oncol. 2013;4(4):409-423.
[35] 黄颖烽,魏亚明,李秋娴,等.大肠癌患者外周血细胞CD133的表达[J].中国组织工程研究与临床康复,2011,15(40):7597-7600.
[36] Duraj FF, Cashin PH. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal and hepatic metastases: a case-control study. J Gastrointest Oncol. 2013;4(4):388-396.
[37] Shafaei S, Sharbatdaran M, Kamrani G, et al. The association between CD166 detection rate and clinicopathologic parameters of patients with colorectal cancer. Caspian J Intern Med. 2013;4(4):768-772.
[38] Shintani M, Sangawa A, Yamao N, et al. Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol. 2013;6(12):2919-2927.
[39] Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res. 2013;5:387-400.
[40] Dhir M, Lyden ER, Smith LM, et al. Influence of margins on disease free survival following hepatic resection for colorectal metastasis: a meta-analysis. Indian J Surg Oncol. 2012; 3(4):321-329.
[41] Bangaru H, Veitla RM, Pigilam M, et al. Comparative Study between Staplers and Conventional(Hand-Sewn) Anastomosis in Gastrointestinal Surgery. Indian J Surg. 2012;74(6):462-467.
[42] 秦海春,刘俊,杜廷义,等.CEA蛋白、CEA mRNA在大肠癌诊断中的应用价值[J].现代预防医学,2012,39(9):2255-2256.
[43] Fathallah RM, Dajani R. Comparison of population based cancer incidence rates among Circassians, Chechans and Arabs in Jordan (1996-2005). Asian Pac J Cancer Prev. 2013;14(10):6035-6040.
[44] Rasool S, Kadla SA, Khan T, et al. Association of a VDR gene polymorphism with risk of colorectal cancer in Kashmir. Asian Pac J Cancer Prev. 2013;14(10):5833-5837.
[45] Pandurangan AK, Esa NM. Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev. 2013;14(10):5543-5552.
[46] Yamashita K, Katoh H, Watanabe M. The homeobox only protein homeobox (HOPX) and colorectal cancer. Int J Mol Sci. 2013;14(12):23231-23243.
[47] Harada K, Harada Y, Beika M, et al. Detection of lymph node metastases in human colorectal cancer by using 5-aminolevulinic acid-induced protoporphyrin IX fluorescence with spectral unmixing. Int J Mol Sci. 2013;14(11): 23140- 23152.
[48] Nazemalhosseini Mojarad E, Kuppen PJ. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer. Immunotherapy. 2013;5(12):1267-1269.
[49] Scartozzi M, Giampieri R, Del Prete M, et al. Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opin Pharmacother. 2014;15(1):143-150.
[50] Douillard JY, Rong A, Sidhu R. RAS mutations in colorectal cancer. N Engl J Med. 2013;369(22):2159-2160.
[51] Jaganathan SK, Supriyanto E, Mandal M. Events associated with apoptotic effect of p-Coumaric acid in HCT-15 colon cancer cells. World J Gastroenterol. 2013;19(43):7726-7734.
[52] Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol. 2013;19(43):7561-7568.
[53] Deng BG, Yao JH, Liu QY, et al. Comparative serum proteomic analysis of serum diagnosis proteins of colorectal cancer based on magnetic bead separation and maldi-tof mass spectrometry. Asian Pac J Cancer Prev. 2013;14(10): 6069-6075.
[54] Kheirelseid EA, Miller N, Chang KH, et al. Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol. 2013;4(4):397-408.